fasudil has been researched along with Glaucoma, Suspect in 1 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fukunaga, T | 1 |
| Ikesugi, K | 1 |
| Nishio, M | 1 |
| Sugimoto, M | 1 |
| Sasoh, M | 1 |
| Hidaka, H | 1 |
| Uji, Y | 1 |
1 other study available for fasudil and Glaucoma, Suspect
| Article | Year |
|---|---|
The effect of the Rho-associated protein kinase inhibitor, HA-1077, in the rabbit ocular hypertension model induced by water loading.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Topical; Animals; Disease Models, Ani | 2009 |